Narrative Review
Recently published articles about Narrative Review
Narrative Review
Validation for the Tardive Dyskinesia Impact Scale, a Patient-Reported Outcome Measure in Valbenazine Clinical Trials
April 29, 2026
The TDIS followed a similar trajectory to other clinician- and patient-reported outcomes measured in tardive dyskinesia clinical trials, and a change of 4 points in total score is considered...
Recent JCP Articles on Narrative Review
Narrative Review
Immune Targeted Therapies for Depression: Antidepressant Effects of Monoclonal Antibodies
June 24, 2024
Immune dysregulation may contribute to treatment resistance in depression. Monoclonal antibodies have shown promise in treating depression when used for inflammatory disorders and may offer new hope for patients...
Recent PCC Articles on Narrative Review
Featured Narrative Review Research
Rounds in the General Hospital
Medical Traumatic Stress and Medical Posttraumatic Stress Disorder Following Illness and Treatment: What Primary Care Providers Need to Know
November 12, 2026
Medical PTSD has been associated with debilitating mental health symptoms and a decreased quality of life, as well as with worse medical outcomes.
Expert Commentary
DT120 for Generalized Anxiety Disorder: Findings From Phase 2b and Phase III Trials
November 11, 2026
Lori Davis, MD, reviews clinical trial findings on DT120, an oral disintegrating tablet formulation of lysergide, for generalized anxiety disorder. She describes efficacy findings across a phase 2b trial...
Narrative Review
Incretin Therapies: A New Tool to Combat Metabolic Consequences of Antipsychotic Use
September 4, 2025
Incretin therapies have emerged as a promising treatment option with potential benefits for mitigating cardiometabolic side effects associated with antipsychotics; however, clinical trials have often excluded psychiatric populations.
Narrative Review
Idiopathic Hypersomnia: Recognition and Management in Psychiatric Practice
June 2, 2025
Idiopathic hypersomnia, characterized by excessive daytime sleepiness (EDS), has an estimated population prevalence up to 1.5%. Psychiatric medications may exacerbate EDS and, conversely, idiopathic hypersomnia treatments may exacerbate psychiatric...